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Summary 
The circumsporozoite protein (CS) covers uniformly the plasma membrane of malaria sporozoites. 
In vitro, CS muhimers bind specifically to regions of the hepatocyte plasma membrane that are 
exposed to circulating blood in the Disse space. The ligand is in the region II-plus of CS,  an 
evolutionarily conserved stretch of the protein that has amino acid sequence homology to a cell 
adhesive motif of thrombospondin. We have now found that intravenously injected CS constructs 
bind rapidly to the basolateral surface of hepatocytes, provided that the recombinant proteins 
contain region II-plus, and that they are aggregated. Significant amounts of CS were not retained 
in any other organ. The striking parallelism between these in vitro and in vivo findings with 
the target specificity of malaria sporozoites, reinforces the hypothesis that the attachment of the 
parasites  to hepatocytes is via region II-plus of CS. 
T 
he binding of malaria sporozoites to liver cells in vitro 
appears to involve an interaction between region II-plus 
of the circumsporozoite protein (CS) 1 with glycosamino- 
glycan (GAG) chains of heparan sulfate proteoglycans (HSPG) 
on the surface of hepatocytes (1). The CS is the major surface 
protein  of malaria  sporozoites.  A  second region  II-plus- 
containing protein, TRAP (2-4) or SSP-2 (5-7),  has been 
identified on the surface of sporozoites from some species of 
malaria sporozoites, but it is scarcely represented on their 
plasma membranes. Although the binding of region II-plus 
to GAG chains may also represent the initial recognition event 
in vivo, some investigators have suggested that before hepa- 
tocyte invasion, sporozoites are retained by specific receptors 
located either on the fenestrated endothelium that lines the 
liver sinusoids, or on Kupffer cells (8). The attached sporozoites 
would then traverse the endothelium, gain access to the Disse 
space, and enter hepatocytes. Nevertheless, the putative non- 
hepatocyte receptors that mediate the attachment of sporozoites 
to liver cells have not been identified. 
Here we have approached this question experimentally, by 
following the fate of recombinant CS injected intravenously 
into mice. Based on our previous in vitro results, we expected 
that CS would home specifically to hepatocytes in vivo, in 
a region II-dependent manner. In addition, we hoped that 
these experiments might reveal nonhepatocyte  receptors for CS. 
1Abbreviations used in this paper: CS, circamsporozoite; GAG, glycos- 
aminoglycan; HSPG, heparin sulfate proteoglyc.ans. 
Materials  and Methods 
Recombinant Proteins.  A schematic  representation of the CS con- 
structs is shown in Fig. 1. The Escherichia coli-derived recombinant 
CS27IVC  (27-123[NANPNVDP]3[NANP]2,300-411) represents 
the complete Plasmodiumfakiparum CS sequence from the T4 iso- 
late, except that the hydrophobic clusters of NH2- and COOH- 
terminal amino acids 1-26 and 412-424 have been ddeted (9, 10). 
The yeast-derived  Falc-1Rfah'pamm T4 recombinant protein (amino 
acids 43-348) was obtained from Chiton Corporation (EmeryviUe, 
CA). Falc-1 terminates in the proline residue that precedes the first 
pair of cysteines in region II-phs (11). 
Antibodies.  The mAb 2A10 (12) is directed against an epitope 
contained in the (NANP)n repeat domain of the R fakiparum CS. 
Mice.  BALB/c  males, from Taconic  Farms, Inc. (Germantown, 
NY), weighing between 15 and 20 g were used. 
FITC Labeling ofmAb 2,,110.  The antibody hbeling was per- 
formed as described by Harlow and Lane (13). 
SlCr Labeling of RBC.  Mouse blood (200/~1) was collected 
from the retroorbital sinus, and washed with PBS, pH 7.4, con- 
taining 1% BSA (BSA/PBS). The RBC pellet was incubated with 
10/tCi of NaSlCrO4 for 30 min, and then washed with BSA/PBS. 
~2sI Labeling.  The recombinant proteins were labeled using io- 
dogen to a specific  activity of "~2.5 x  10  s cpm//tg. To reduce the 
amount of oxidative damage to the proteins, 1 mCi of '2sI in 10 
~1 of 0.1 M sodium phosphate buffer was oxidized in a glass tube 
precoated with iodogen for 5 rain. 10/~1 were then transferred to 
another tube, and incubated for 5 min on ice with 10/~1 (10/tg) 
of CS27IVC or Falc-1. The free iodide was removed by filtration 
in Sephadex G-25 (Isohb Inc., Akron, OH), and dialyzed against 
50 mM Tris-HC1, 75 mM NaC1, pH 7.4 (buffer A). 
695  J. Exp. Med. ￿9  The Rockefeller  University  Press ￿9 0022-1007/94/02/0695/07 $2.00 
Volume 179  February  1994  695-701 Figure  1.  Schematic representation of the recombinant CS. 
Isolation of CS27IVC Muhimers.  Radiolabeled  CS27IVC was 
applied to a 1-ml heparin-Sepharose column (Sigma Chemical Co., 
St. Louis,  MO) that had been preequilibrated with 50 mM Tris- 
HC1, 75 mM NaC1, 1% BSA, 0.05% Tween-20 (Bio-Rad Labora- 
tories,  Hercules, CA), pH 7.4 (buffer B),  and washed with five- 
column volumes of the same buffer. The bound material was eluted 
with  1 ml 50 mM Tris-HC1,  1.5 M  NaC1, pH 7.4,  and dialyzed 
against buffer A. 
Clearance Studies.  Mice were anaesthetized with ether, and in- 
jected with 10  s cpm of 12Sl-labeled CS27IVC or Falc-1 via the peri- 
orbital sinus.  At 2,  5,  and  15 min after injection,  the mice were 
exsanguinated,  the organs removed, rinsed in Tris-buffered saline 
blotted dry on filter paper, and counted for radioactivity. To esti- 
mate the amounts of blood contaminating the various organs, we 
repeated the same procedure in mice injected with 100 #1 (1.5  x 
l0  s cpm) of SlCr-labeled RBC. The mean volumes of blood in the 
liver, spleen, and kidney of the exsanguinated animals were 75, 24, 
and 35 #1, respectively.  In all other organs the amount of blood 
was negligible,  i.e.,  <15/~1.  The percent of injected dose of CS 
that was retained in the various organs was calculated as described 
in the legend to Fig. 4, after subtracting the CS counts from the 
contaminating blood. 
In other experiments,  we used light  and electron  microscopy 
to localize CS in the various organs. The mice were injected with 
100 #g (i.v.) of unlabeled CS27IVC or Falc-1 via the retroorbital 
plexus.  They were exsanguinated 5 min after injection, the organs 
were removed, rinsed in TBS, blotted dry, and then snap frozen 
in liquid nitrogen for light microscopy. For electron microscopy, 
the organs were cut into  small pieces  and fixed  in  a mixture of 
0.1%  glutaraldehyde  and 4%  paraformaldehyde. 
Light Microscopy.  The frozen tissue was embedded in Tissue 
Tek ornithine carbonyl transferase (Miles Inc., Naperville, IL) and 
cut into 5-#m sections.  Sections were dried for 30 min, fixed for 
10 min in 4% paraformaldehyde, and either used immediately or 
stored at 40C in PBS containing 1% BSA, 0.5% Tween-20. After 
blocking with the same buffer, the sections were incubated with 
mAb 2A10 conjugated to FITC, and examined in  a fluorescence 
microscope. 
Electron Microscopy.  The fixed liver specimens were dehydrated 
in ethanol and embedded in Lowicryl K4M (Ted Pella,  Redding, 
CA) at  -  20~  After UV polymerization, sections were cut with 
a RMC MT-7 ultramicrotome (Research and Manufacturing Co., 
Tucson, AZ) and stained by sequential incubation with 15/~g/ml 
mAb 2A10 and protein A gold 10 nm (PAG10) (1:30,  Amersham 
Corp., Arlington, IL) (14). Control sections were stained only with 
the gold conjugate. Photographs were taken with an electron mi- 
croscope (EM 910; Carl Zeiss,  Inc., Thornwood,  NY). 
Results 
Isolation of CS27IVC Muhimers by A.~nity Chromatography 
on Heparin-Sepharose.  We have previously found that only 
the multimers  of CS27IVC bind in vitro  to  the basolateral 
domain  of hepatocytes,  and  to  HepG2  cells  (14).  In  those 
studies we used molecular sieving chromatography to sepa- 
rate multimers from monomers of CS27IVC.  However,  the 
separation of multimers  from monomers by this  procedure 
is  sometimes  incomplete.  Since  the  CS  multimers  bind  to 
the GAG chains of HSPG (1),  in the present studies we iso- 
lated  the  CS  multimers  by  affinity  chromatography  on 
heparin-sepharose. 
As shown in Fig. 2 a, "30%  of the radiolabeled CS27IVC 
bound to the heparin-sepharose column, and the bound mol- 
ecules were eluted with a buffer containing  a high salt con- 
centration.  SDS-PAGE analysis under nonreducing conditions 
showed  that  the  breakthrough  peak  contained  only  CS 
monomers, while the heparin-binding material contained var- 
ious  CS multimers  as well as monomers  (Fig.  2  b).  Under 
reducing  conditions,  a  single band  corresponding  to  a  CS 
monomer was detected  in proteins  under both peaks,  indi- 
cating  that  the  CS  multimers  consist  of mixed  aggregates 
of disulfide-linked  dimers,  trimers,  etc.,  and  noncovalently 
bound monomeric CS.  The CS27IVC fractions obtained by 
filtration in sizing columns (14), and by affinity chromatog- 
Figure  2.  Isolation of CS27IVC aggregates by affanity  chromatography 
in a heparin-sepharose column. (a) 12SI-labeled  CS27IVC was applied to 
a heparin-sepharose column preequilibrated in buffer A. The column was 
washed with 5 ml of the same buffer, and the bound CS27IVC was eluted 
with 50 mM Tris-Cl, 1.5 M NaCI, pH 7.4. The ordinates represent the 
cpm in 10 #1 of each fraction. (b) 10/~1 of selected fractions were run 
on 10% SDS-PAGE  under nonreducing conditions, the gel was dried, and 
subjected to radioautography. As shown, only the aggregated CS27IVC 
bound to the heparin-sepharose column. 
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the CS multimers bind to HepG2 cells  (data not shown). 
Clearance of CS27IVC ancl Fak-1.  Radiolabeled Falc-1, and 
the  aggregated  and  monomeric fractions  of radiolabeled 
CS27IVC proteins were injected intravenously into mice. The 
animals were killed 2, 5, and 15 min later, and the amounts 
of CS in the blood, and in the various organs were measured. 
There were striking differences in the pattern of clearance 
of muhimers of CS27IVC, as compared with that of Falc-1, 
or of the monomers of CS27IVC.  Only '~40%  of the in- 
jected CS monomers, or of Falc-1 counts were recovered in 
the blood and in various organs between 2 and 15 min after 
injection, and 4%  or less were associated with the liver at 
any time (Fig.  3, a and b). In sharp contrast, 80% or more 
of the injected multimer CS counts were recovered, and most 
were in the liver,  i.e.,  45%  at 2 min, 55%  at 5 rain,  and 
70%  at 15 min. There was practically no accumulation of 
CS muhimers in the bladder, heart, kidney, large intestine, 
lung, small intestine, stomach, spleen, or thyroid (Fig. 3 c). 
The CS27IVC Aggregates Accumulate on the Microvilli of  He- 
t,atocytes.  To define the cellular localization of the CS, we 
performed immunofluorescence staining of frozen sections 
of various organs of mice injected intravenously 15 min ear- 
lier with larger amounts (100/~g) of unlabeled CS27IVC or 
Falc-1. No staining with FITC-labeled mAb 2A10 was seen 
in the livers (Fig. 4 a) or kidneys of mice injected with Falc-1. 
In animals injected with CS27IVC,  the recombinant was 
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readily detected in the liver (Fig. 4 b), but not in the kidney 
(Fig. 4 c) or other organs. In the liver, the bound CS closely 
followed the contours of the sinusoids, suggesting accumu- 
lation in the Disse spaces. By electron microscopy, the gold 
label was detected in the Disse spaces of the liver (Fig. 5 a), 
where single or doublets of gold particles were found in close 
association with the microvilli of hepatocytes (Fig. 5 b). No 
gold label was found on endothelial or Kupffer cell surfaces. 
Discussion 
We show here that intravenously injected CS rapidly enters 
the Disse space and binds to the basolateral surface of hepa- 
tocytes, but not to endothelial or Kupffer cells.  Only ag- 
gregated CS-containing region II-plus bound to hepatocytes. 
As shown dsewhere (14),  these were precisely the require- 
ments for the binding of CS to HepG2 calls, and to frozen 
sections of liver. Similar mechanisms appear therefore to be 
involved in the recognition of the CS by hepatocytes in vitro 
and in vivo. The in vivo liver staining pattern shown in Fig. 
4 is almost identical to that obtained by direct incubation 
of CS27IVC with frozen sections of that organ (14).  The 
only difference between the two patterns resides in the cen- 
tral veins, which are negative by in vivo labeling, and posi- 
tive by in vitro labeling. The most likely explanation for this 
apparent discrepancy is that there are no fenestrae in the cen- 
trolobnlar vein endothelium (15). Therefore, the underlying 
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Figure 3.  Clearance of aggregated CS27IVC by the liver. Radiolabded 
monomeric CS27IVC (a), Falc-1 (b), and multimeric CS27IVC  (c) were 
injected into the retroorbital sinuses of mice. The animals were killed 2, 
5,  and  15 min after  injection. To estimate  the amounts  of blood con- 
taminating the various organs, we repeated the same procedure  in mice 
injected with 100/tl (1.5  x  10  s cpm) of slCr-labded RBC. The mean 
volumes of blood in the liver, spleen, and kidney  of the exsanguinated 
animals were 75, 24, and 35/*1, respectively. In all other organs the amount 
of blood was negligible, i.e., tess than 15/~1. The percent of the injected 
CS counts retained  in the organs  of each mouse (percent  retained cpm) 
was calculated after subtraction  of the CS counts from the contaminating 
blood. Percent retained  cpm  =  corrected  cpm per organ/total injected 
dose  x  100. The total blood vohme was calcuhted as in (16). From left 
to right, the bars represent clan assodated with: bhdde~ heart, two kidneys, 
large intestine, liver, two lungs, small intestine,  stomach, spleen, thyroid, 
and blood. Each bar represents mean values _+ SD of cpm in organs from 
three  mice. 
697  Cerami et al. Figure  4.  CS27IVC localizes to the sinusoids of the liver. Mice were injected with 100/~g  CS271VC or Falc-1, and 5 min later they were killed. 
The livers and kidneys were removed,  washed in TBS, blotted dry, and snap frozen in liquid nitrogen. Frozen tissues were stained with mAb 2A10 
conjugated to FITC. (a) Liver of a mouse injected with Falc-1. (b) Liver of a mouse injected with CS27IVC. (c) Kidney of a mouse injected with CS27IVC. 
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699  Cerami et al. Figure  5.  Ultrastructural  localization  of CS271VC in the liver. Mouse  liver was fixed 15 rain after  intravenous  injection  of 100/~g CS27IVC. The 
tissue was embedded  in Lowicryl  K4M, and sections were stained with mAb 2A10 and protein A-coated gold particles PAG10. (a) The gold label 
is associated  with hepatocyte  microvilli  in the Disse space (D). There is no label on a Kupffer  cell (K) in the sinusoidal  lumen. (b) CS is found  between 
the hepatocyte  (H) microvilli  within the Disse space  (D), whereas the endothelial  cell surface facing the sinusoidal lumen (S) is unlabeled (arrows). 
M, mitochondrium.  Bars, 1 /~m. 
hepatocytes are not accessible to the recombinant CS27IVC 
circulating in the sinusoids.  In an analogous fashion, the 
basolateral domain of the kidney proximal epithelia are stained 
by CS27IVC in frozen sections (1), but there is no accumula- 
tion of CS27IVC in vivo in the kidney (Fig. 4 c). The renal 
tubular epithelia are separated from the blood circulation by 
fenestrated epithelia, but the fenestrae in this case are closed 
by a diaphragm. 
Although the Disse space is accessible to the blood circu- 
lation and to the purified CS, a confounding remaining ques- 
tion is how sporozoites cross the fenestrated endothelium of 
the liver sinusoids, since the diameter of the parasites (1/~m) 
is greater than the diameter of the fenestrae (average, 0.1/~m). 
However, the diameter of the fenestrae may vary in vivo with 
changes in blood pressure, or sporozoites may be flexible and 
squeeze through a smatl aperture. Furthermore, hepatocyte 
microvilli (or the GAG chains of the HSPGs from the surface 
of microvilli), may in fact traverse the fenestrae and protrude 
in the lumen of the sinusoids,  thus entering in direct contact 
with the circulating blood. 
The present findings do not prove  that during infection 
by malaria sporozoites the initial recognition event is the 
binding of region II-plus of CS, and perhaps of TRAP/SSP2, 
to hepatocyte microvilli. Nevertheless,  they provide a plau- 
sible  explanation for  the  target cell  specificity  of malaria 
sporozoites, and, more importantly, suggest new experimental 
strategies  to prevent sporozoites from reaching their target. 
Outside the malaria field,  our findings raise the intriguing 
possibility that the in vivo specificity of region II-plus for 
hepatocytes can be utilized for the targeting of drugs, or of 
genetic materials to hepatocytes in vivo. For example, the in- 
corporation of the region II-plus amino acid sequence into 
surface proteins of a recombinant virus may deliver it to he- 
patocytes. 
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